NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
10,770
+120 (1.13%)
At close: Jul 4, 2025, 3:30 PM KST
67.24%
Market Cap 133.02B
Revenue (ttm) 1.30B
Net Income (ttm) 408.03M
Shares Out 12.13M
EPS (ttm) 120.00
PE Ratio 91.42
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,559
Average Volume 5,471
Open 10,510
Previous Close 10,650
Day's Range 10,500 - 11,250
52-Week Range 4,505 - 11,800
Beta 0.31
RSI 66.83
Earnings Date n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.